Home > Insider Trading > Filing (0001209191-20-056790)

Filing Details

Accession Number:: 0001209191-20-056790
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-11-03 19:56:48
Reporting Period:: 2020-10-30

Accepted Time:: 2020-11-03 19:56:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348911	Kalvista Pharmaceuticals Inc.	KALV	Pharmaceutical Preparations (2834)	200915291

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1397906	Albert Cha	C/O Kalvista Pharmaceuticals, Inc. 55 Cambridge Parkway, Suite 901E Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-30	68,255	$17.17	1,090,748	No	4	P	Indirect	By Vivo Opportunity Fund, L.P.
Common Stock	Acquisiton	2020-10-30	47,431	$17.34	1,138,179	No	4	P	Indirect	By Vivo Opportunity Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Vivo Opportunity Fund, L.P.
No	4	P	Indirect	By Vivo Opportunity Fund, L.P.

Footnotes

The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.26 to $17.25 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The shares are held of record by Vivo Opportunity Fund, L.P. The general partner of the holder is Vivo Opportunity, LLC, of which the Reporting Person is a voting member. The Reporting Person may be deemed to share voting and dispositive power over these shares with four (4) other voting members. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.26 to $17.35 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.